Physician profile
Alkesh D Patel
NPI 1679505549
$42,165.60
in general payments reported to CMS, 2019-2025
45 companies · $1,248 in 2025
The $1,248 reported for 2025 was more than what 89% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,031 · 2020: $23K · 2021: $12K · 2022: $2,338 · 2023: $1,194 · 2024: $1,128 · 2025: $1,248.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,570.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,569.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $19,141.30 | 2020-2022 | |
| Allergan, INC. | $12,168.93 | 2019-2021 | |
| Novo Nordisk INC | $1,799.27 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Amgen INC. | $960.41 | 2019-2025 | Evenity |
| Lilly USA, LLC | $817.25 | 2019-2025 | Jardiance, Mounjaro, Zepbound |
| Amarin Pharma, INC. | $606.97 | 2019-2023 | |
| Janssen Pharmaceuticals, INC | $536.13 | 2019-2021 | |
| Nestle Healthcare Nutrition INC. | $474.27 | 2020-2023 | |
| Merck Sharp & Dohme LLC | $458.11 | 2019-2025 | Gardasil 9, Capvaxive, Gardasil |
| Pfizer INC. | $447.46 | 2019-2025 | |
| Abbvie INC. | $423.18 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $359.68 | 2019-2023 | |
| Kowa Pharmaceuticals America, INC. | $358.71 | 2019-2025 | Livalo, Seglentis, Zoryve |
| Cepheid | $315.00 | 2020 | |
| Biohaven Pharmaceutical Holding Company LTD. | $290.34 | 2022 |
Show all 45 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alkesh Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.